Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger coho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Biol Ther
Asıl Yazarlar: Pizzuti, Laura, Sergi, Domenico, Sperduti, Isabella, Lauro, Luigi Di, Mazzotta, Marco, Botti, Claudio, Izzo, Fiorentino, Marchetti, Luca, Tomao, Silverio, Marchetti, Paolo, Natoli, Clara, Grassadonia, Antonino, Gamucci, Teresa, Mentuccia, Lucia, Magnolfi, Emanuela, Vaccaro, Angela, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Sini, Valentina, Sarobba, Maria G, Fabbri, Maria Agnese, Moscetti, Luca, Astone, Antonio, Michelotti, Andrea, De Angelis, Claudia, Bertolini, Ilaria, Angelini, Francesco, Ciliberto, Gennaro, Maugeri-Saccà, Marcello, Giordano, Antonio, Barba, Maddalena, Vici, Patrizia
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902232/
https://ncbi.nlm.nih.gov/pubmed/29336662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1416938
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller